Wave Life Sciences Ltd. - 8-K Filing
Wave Life Sciences reports Q2 2026 financial results and updates on clinical trials, including WVE-007 in obesity and WVE-006 for AATD (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $WVE